The supply chain you tolerate is the risk you carry
Late Certificates of Analysis. Purity that drifts between batches. Suppliers who operate in compliance grey areas. The hours you spend babysitting due diligence are hours not spent on patient outcomes or market growth. This is not an acceptable cost of doing business — it is an unforced error the industry has normalised.
REGULATORY INTELLIGENCE
The Market Is Changing.
The Grey Area Is Closing.
In 2024, the FDA moved 14 peptides toward Category 2 reclassification. The TGA issued safety advisories on unapproved peptides in April 2026. CBP customs seizure rates are climbing. State-level enforcement actions are no longer theoretical — they are operational.
These are not isolated events. They are the systematic elimination of grey-market channels that many suppliers have depended on for years. The documentation bar is rising, and the suppliers who treated compliance as optional are being removed from the market — quietly, permanently.
The market is bifurcating: infrastructure-grade supply partners on one side, and everyone else on the other.
The cost of discovering which category your supplier falls into during an audit is not a setback — it is a business-ending event. The question is no longer whether your supply chain will be tested, but when.
Explore Supply Partnerships
We Built mCare Because This Problem Shouldn't Exist
The professionals responsible for patient outcomes should never have to second-guess their supply inputs. mCare is the upstream bioactive supply partner for licensed distributors, compounding pharmacies, and clinical institutions that require pharmaceutical-grade compounds delivered with batch-level COA documentation, verified cold-chain logistics, and cross-border customs clearance. We are not a marketplace. Not a catalogue. Not a peptide company. We are infrastructure.
We don't sell hope. We sell certainty.
-
Every batch ships with a full Certificate of Analysis Verified upstream supplier relationships with pharmacopeial-grade documentation that satisfies FDA, TGA, and EU regulatory standards proactively — not reactively.
-
Cold-chain integrity is documented, not assumed Cross-border cold-chain logistics with verified temperature monitoring and documented customs clearance at every transit point.
-
Compliance documentation is built in, not bolted on Infrastructure-level compliance that meets pharmacopeial, FDA, TGA, and EU standards — because your regulatory exposure is our engineering problem.
-
Supply Partnerships are the mechanism, not transactions The foundational commercial relationship through which this infrastructure becomes operational for your practice or institution.
Principles operationalised, not advertised
Six commitments. Each one verifiable. Every one backed by infrastructure, not intention.
-
Uncompromised Purity
Every compound meets or exceeds pharmacopeial standards. Batch-level Certificates of Analysis accompany every shipment — no exceptions, no thresholds below which we relax verification.
-
Full Traceability
Every step from source to delivery is documented and verifiable. Our Real-Time Shipment Traceability Portal provides live shipment status, temperature logs, and documentation readiness notifications before arrival.
-
Supply Chain Integrity
Infrastructure, not shortcuts. Whether catalogue or custom-sourced, every compound receives the same documentation standards and verification rigour. A partner's needs should never be limited by what is already on a shelf.
-
Professional Trust
Earned through consistency, not promises. Our Partner Onboarding Acceleration System provides a structured pathway from first contact to formalised partnership — transparent at every stage.
-
Regulatory Alignment
Proactive compliance. Partner Intelligence Briefings deliver regulatory change alerts, customs clearance updates, and jurisdiction-specific compliance developments to partners before changes affect their operations.
-
Accountability
If it ships under our name, we stand behind it completely. No disclaimers, no conditional warranties. The documentation trail exists so that accountability is not a question — it is a fact.
Your Path Into the mCare Network
Three structured entry points — each built on the same verification infrastructure, each matched to where you are and where you're going.
Core Supply Partnership
The foundational relationship. Wholesale access to clinical-grade bioactive compounds, with batch-level COAs, cold-chain delivery, and contractual supply guarantees. One verified upstream source — for every order, every compound.
- Batch-level Certificates of Analysis
- Cold-chain verified delivery
- Contractual supply guarantees
- Dedicated account coordination
Custom Sourcing
When your operation requires a compound outside the standard catalogue, the same verification and documentation infrastructure applies. Your partnership is not limited by a product list — it's extended by our sourcing capability.
- Full documentation trail on custom compounds
- Same verification standards as catalogue supply
- Dedicated sourcing specialist assigned
- Transparent lead-time communication
Territory Partnership
The earned milestone. Formalised distribution rights within a defined geographic market — available exclusively to partners who have demonstrated consistent volume through an active Supply Partnership. Territory protection, volume-tiered pricing, co-marketing provisions, and priority allocation.
- Exclusive geographic territory protection
- Volume-tiered pricing structure
- Co-marketing and brand support provisions
- Priority allocation during supply constraints
- Qualification-based access — not application-based
Every partnership begins with a structured evaluation — a conversation, not a transaction. Explore the pathway that matches your operation.